RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Strengths and limitations of commercial tests for hepatitis C virus RNA quantification
Morishima, C., Chung, M., Ng, KW., Brambilla, D., & Gretch, DR. (2004). Strengths and limitations of commercial tests for hepatitis C virus RNA quantification. Journal of Clinical Microbiology, 42(1), 421-425. https://doi.org/10.1128/JCM.42.1.421-425.2004
The sensitivity of the Roche COBAS Monitor v.2.0 test was slightly better than that of the Bayer bDNA 3.0 test, but the Monitor test underquantified specimens by 2.5- to 10.6-fold even at relatively low hepatitis C virus RNA concentrations. Dilution prior to assay minimally decreased the reproducibility of the Monitor assay, leading to the recommendation for all specimens to be diluted 1:100 prior to testing by this assay